EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes

Philipp E Hartrampf, Aleksander Kosmala, Sophie Alwers, Franziska Lutz, Sebastian E Serfling, Natalie Hasenauer, Christof Däubler, Alexander Meining, Andreas K Buck, Rudolf A Werner, Alexander Weich

European Journal of Nuclear Medicine and Molecular Imaging · 2026-11 · 53 (13) · 8322-8332

DOI: 10.1007/s00259-026-08130-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 14.08.2026. Verfasst von Philipp E Hartrampf und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Wuerzburg, Oberdürrbacherstraße 6, 97080, Wuerzburg, Germany. Hartrampf_P@ukw.de. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Patient Selection, Receptors, Peptide. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patient selection for rechallenge peptide receptor radionuclide therapy (re-PRRT) in neuroendocrine tumors (NET) remains poorly defined. As re-PRRT is increasingly considered in clinical practice, identifying patients most likely to benefit has become a critical yet unresolved question. This study evaluated the efficacy and safety of re-PRRT and aimed to identify pragmatic factors associated with retreatment benefit. Materials and methods This retrospective study included 37 patients with neuroendocrine tumors (NET). Kaplan–Meier estimates were used to evaluate progression-free survival (PFS) following initial (i-PRRT) and re-PRRT. Baseline laboratory parameters were compared between treatment courses, and SSTR-targeted PET metrics (SUV mean , SUV max , and SSTR-positive tumor volume) were assessed at baseline and follow-up. Univariable Cox regression identified prognostic factors for PFS. Adverse events were graded according to CTCAE v5.0.

Results

Median PFS was 32 months after i-PRRT and 17 months after re-PRRT, with disease progression observed in 20/37 patients. Longer PFS following initial therapy was associated with improved outcome after retreatment (per month, HR 0.96, 95% CI 0.93–0.999; p < 0.05). In an exploratory analysis, patients with an initial PFS exceeding 24 months demonstrated a longer median PFS after re-PRRT than those with shorter initial PFS (19 vs. 4 months; log-rank p = 0.02). Higher baseline CRP was significantly associated with shorter PFS after i-PRRT (per mg/dl, HR 8.8, 95% CI 1.2–58.6; p < 0.05), whereas no such association was observed for re-PRRT (per mg/dl, HR 0.79, 95% CI 0.13–3.8; p = 0.8). Instead, higher baseline LDH was significantly associated with shorter PFS following re-PRRT (per U/l, HR 1.007, 95% CI 1.000–1.014; p < 0.05). No PET-derived baseline parameter correlated with PFS. RECIST indicated predominantly stable disease across treatment courses, although responses were less favorable at retreatment. No grade ≥ 3 toxicities were observed during re-PRRT.

Conclusion

Re-PRRT represents a feasible treatment option for selected NET patients. Duration of disease control following initial PRRT was associated with outcome after re-PRRT and may represent a clinically relevant marker for patient selection. The exploratory 24-month threshold requires prospective validation before clinical implementation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsPatient SelectionReceptors, PeptideHumansFemaleMaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedAdultTime FactorsRetreatment

Stichwörter der Autor:innen

DOTATATEDOTATOCGEP NETPFSPRRTRetreatment

Substanzen

Receptors, Peptide

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Wuerzburg, Oberdürrbacherstraße 6, 97080, Wuerzburg, Germany. Hartrampf_P@ukw.de.
  • University Hospital Wuerzburg, ENETS Center of Excellence, Wuerzburg, Germany. Hartrampf_P@ukw.de.
  • Department of Nuclear Medicine, University Hospital Wuerzburg, Oberdürrbacherstraße 6, 97080, Wuerzburg, Germany.
  • University Hospital Wuerzburg, ENETS Center of Excellence, Wuerzburg, Germany.
  • Department of Internal Medicine II, Gastroenterology, University Hospital Wuerzburg, Wuerzburg, Germany.
  • Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany.

Förderung

  • Universitätsklinikum Würzburg

Zitieren

APA

Hartrampf, P. E., Kosmala, A., Alwers, S., Lutz, F., Serfling, S. E., Hasenauer, N., Däubler, C., Meining, A., Buck, A. K., Werner, R. A., & Weich, A. (2026). Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes. European Journal of Nuclear Medicine and Molecular Imaging, 53(13), 8322-8332. https://doi.org/10.1007/s00259-026-08130-8

Vancouver

Hartrampf PE, Kosmala A, Alwers S, Lutz F, Serfling SE, Hasenauer N, et al. Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(13):8322-8332. doi:10.1007/s00259-026-08130-8

BibTeX
@article{Hartrampf2026,
  author = {Hartrampf, Philipp E and Kosmala, Aleksander and Alwers, Sophie and Lutz, Franziska and Serfling, Sebastian E and Hasenauer, Natalie and Däubler, Christof and Meining, Alexander and Buck, Andreas K and Werner, Rudolf A and Weich, Alexander},
  title = {Patient selection for PRRT rechallenge in neuroendocrine tumors: impact of initial response duration on outcomes},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {13},
  pages = {8322--8332},
  doi = {10.1007/s00259-026-08130-8}
}
Kostenlos starten →